Important information: The value of investments and the income from them, can go down as well as up, so you may get back less than you invest.

Another week, another potentially life-changing vaccine. This time it is the turn of US biotech group Moderna, which has said its vaccine has proven to be 94.5% effective in late-stage trials. It is more very good news in the hunt for an effective coronavirus vaccine and it immediately had a positive impact on global stock markets.

Just as we saw after the revelation last week that Pfizer and BioNTech had scored a breakthrough, Moderna’s news yet again sent stocks left behind in the pandemic soaring. The real hope of an end in sight and a return to ‘normal’ life - and with it the prospect of people once again hopping on planes to travel abroad for business and leisure - has brought some much-needed hope to the beleaguered airlines sector.

For easyJet (EZJ), the budget airline, last week’s 35% boost to its share price saw it claw back most of the losses it has suffered over the course of 2020. But this is far from game over, just yet. And today has been a sharp reminder of that.

Showing just how hard hit it - and the rest of the travel sector - has been by the pandemic, easyJet today posted its first ever annual loss in its 25-year history. Pre-tax profits slid £1.27 billion into the red as revenues more than halved, with planes were left grounded by the pandemic.

So much hinges on the success of a vaccine for the likes of easyJet. Without an end to the pandemic its fate looks sealed. There is no question that the roll-out of a successful vaccine is a game-changer. But there is a very long way to go yet.

Even with a number of viable vaccines, it will take time to vaccinate everyone - or a sufficient number globally - to contain the pandemic. And it is this timeframe that is likely to cause the most harm to the companies that have seen their businesses hardest hit by the national lockdowns and global travel bans.

Never before has the fate of two such seemingly disparate stock market sectors - biotech and airlines - been so closely correlated. How many times have we been told since the start of this pandemic that “the science” will guide us? Well now “the science” could single-handedly save the airline industry.

For the time being though things are unlikely to get much better very quickly at all. Today easyJet said it expects to fly no more than about 20% of planned capacity for the first quarter of 2021.

Speaking on BBC Radio 4's Today programme easyJet chief executive Johan Lundgren described the arrival of a successful vaccine as “a very critical part of the recovery". He said that such is the latent demand for travel that on the day the news broke of the success of the Pfizer vaccine, bookings for the airline up were by almost 50%.

And of course, easyJet is not alone. It and British Airways-owner International Consolidated Airlines Group (IAG), were two stocks upgraded, from neutral to buy, by analysts at Bank of America Merrill Lynch as soon as the positive update on a potential Covid vaccine broke.

Fellow budget airline and Wizz Air (WIZZ) also got a special mention as one of the broker’s “top picks” favourable for their exposure to leisure travel and their strong balance sheets. In a note, the broker forecasts that airline industry revenues will be back to around 80% of pre-pandemic levels by 2022.

There is no question that the beleaguered airline sector is waiting with baited breath for a viable vaccine and clearance to properly take off once this is all over. Investors will be doing the same. Just be prepared to be in it for the long haul when checking out low-cost carrier stocks, because there is still a lot of potential turbulence ahead.

More on easyJet

Important information: Reference to specific securities should not be construed as a recommendation to buy or sell these securities and is included for the purposes of illustration only. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Investors should note that the views expressed may no longer be current and may have already been acted upon. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser.

Topics Covered:

UK; Active investing; Shares; Volatility

Latest articles

What did the Chancellor tell us this week?

What the UK spending plans mean for business


Graham Smith

Graham Smith

Market Commentator

Is there a case to be made for investing in India?

Why it may be worth considering one of the world’s largest economies


Toby Sims

Toby Sims

Fidelity Personal Investing

Why Countryside Properties is in need of a makeover

The property developer has Covid and the regulator on its back


Emma-Lou Montgomery

Emma-Lou Montgomery

Fidelity Personal Investing